MedTrace Logo

NI-0401 in Patients With Acute Renal Allograft Rejection

NCT00805909 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-06-09

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and tolerability of NI-0401 and whether NI-0401 can reverse BpACR.

Conditions

  • Acute Renal Transplant Rejection

Interventions

DRUG

NI-0401

5 daily infusions with escalating doses of NI-0401

Sponsors & Collaborators

  • Light Chain Bioscience - Novimmune SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00805909 on ClinicalTrials.gov